This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claims 1-2 cancelled.

3. (Previously amended) The recombinant nucleic acid molecule of claim 6 wherein said nucleotide sequence encodes a fusion protein encoding NS4 or NS5 or any combination thereof.

4. (Previously amended) The recombinant nucleic acid molecule of claim 6 wherein said nucleotide sequence encodes a fragment of at least 50 amino acids of NS4 or NS5.

Claim 5 cancelled.

6. (Previously amended) A recombinant nucleic acid molecule comprising a nucleotide sequence encoding hepatitis C virus NS4 or NS5 protein wherein said nucleotide sequence is operably linked to regulatory elements, said regulatory elements comprising a promoter, enhancer, polyadenylation sequence, and a 5' untranslated region (5'-UTR), said 5'-UTR comprising at least the 9 most 3' nucleotides of a 5' UTR of hepatitis C virus.

7. (Original) The recombinant nucleic acid molecule of claim 6 wherein said promoter is a cytomegalovirus promoter and said enhancer is a Rous Sarcoma Virus enhancer.

8. (Previously amended) A recombinant host cell comprising a nucleic acid molecule of claim 6.

Claims 9-16 cancelled.

17. (Previously amended) A method of inducing an immune response against hepatitis C virus in a human uninfected by hepatitis C virus comprising administering to said human a recombinant nucleic acid molecule comprising a nucleotide sequence encoding a hepatitis C

virus nonstructural protein in an amount effective to induce an immune response against hepatitis C virus.

18. (Original) The method of claim 17 wherein said nonstructural protein is selected from the group consisting of NS3, NS4, and NS5.

19. (Original) The method of claim 17 wherein said nucleotide sequence encodes a fusion protein encoding NS3, NS4, or NS5, or any combination thereof.

20. (Original) The method of claim 17 wherein said nucleotide sequence encodes a fragment of at least 50 amino acids of nonstructural protein selected from the group consisting of NS3, NS4, and NS5.

21. (Original) The method of claim 18 wherein said nucleotide sequence is operably linked to regulatory elements functional in human cells.

22. (Original) The method of claim 21 wherein said nucleotide sequence is operably linked to a promoter, enhancer, polyadenylation sequence, and optionally 5' UTR of hepatitis C virus.

23. (Original) The method of claim 22 wherein said promoter is a cytomegalovirus promoter and said enhancer is a Rous Sarcoma Virus enhancer.

24. (Original) The method of claim 17 wherein said immune response comprises a cellular response.

25. (Original) The method of claim 17 wherein said immune response comprises a humoral response.

26. (Original) The method of claim 17 wherein said recombinant nucleic acid molecule is in a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent.

27. (Original) The method of claim 26 wherein said pharmaceutical composition further comprises a facilitator.

28. (Original) The method of claim 27 wherein said facilitator is bupivacaine.

Claims 29-33 cancelled

34. (Previously added) A recombinant nucleic acid molecule comprising a nucleotide sequence encoding a hepatitis C virus NS3 protein, wherein said nucleotide sequence is operably linked to a promoter, enhancer, polyadenylation sequence, and the entire 5' UTR of hepatitis C virus or a fragment thereof including the last nine nucleotides of the hepatitis C virus 5' UTR.

35. (Previously added) The recombinant nucleic acid molecule of claim 34 wherein said nucleotide sequence encodes a fusion protein encoding NS3 or a combination of NS3 with NS4 or NS5, or a combination of NS3 with both NS4 and NS5.

36. (Previously added) The recombinant nucleic acid molecule of claim 34 wherein said nucleotide sequence encodes a fragment of at least 50 amino acids of NS3.

37. (Previously added) The recombinant nucleic acid molecule of claim 34 wherein said promoter is a cytomegalovirus promoter and said enhancer is Rous Sarcoma Virus enhancer.

38. (Previously added) A recombinant host cell comprising a nucleic acid molecule of claim 34.

Claims 39 to 46 cancelled.